Literature DB >> 16738741

Pelvic organ prolapse: demographics and future growth prospects.

Harold P Drutz1, May Alarab.   

Abstract

Pelvic Organ Prolapse (POP) is the hidden epidemic. Demographic studies have shown that women over the age of eighty are the fastest growing population segment in the United States and Canada. Over the next thirty years the rate of women who will seek treatment for POP will double. Risks for the development of POP have been categorized into factors that predispose, incite, promote, and decompensate. Connective tissue disorders may play a role in the pathogenesis which may involve a reduction in total collagen content secondary to increased collagenolytic activity. Eventually clinicians may be able to identify women who may be genetically predetermined to develop POP. The role of adjuvant materials in performing reconstructive pelvic surgery may improve success rates, but evidence based medicine and randomized controlled trials are currently lacking.

Entities:  

Mesh:

Year:  2006        PMID: 16738741     DOI: 10.1007/s00192-006-0102-1

Source DB:  PubMed          Journal:  Int Urogynecol J Pelvic Floor Dysfunct


  23 in total

1.  Procedures for pelvic organ prolapse in the United States, 1979-1997.

Authors:  Sarah Hamilton Boyles; Anne M Weber; Leslie Meyn
Journal:  Am J Obstet Gynecol       Date:  2003-01       Impact factor: 8.661

2.  Excretion of collagen derived peptides is increased in women with stress urinary incontinence.

Authors:  Leslie Kushner; Mahesh Mathrubutham; Tracey Burney; Robert Greenwald; Gopal Badlani
Journal:  Neurourol Urodyn       Date:  2004       Impact factor: 2.696

3.  Clinical presentation of enterocele.

Authors:  Q Chou; A M Weber; M R Piedmonte
Journal:  Obstet Gynecol       Date:  2000-10       Impact factor: 7.661

4.  The distribution of pelvic organ support in a population of female subjects seen for routine gynecologic health care.

Authors:  S E Swift
Journal:  Am J Obstet Gynecol       Date:  2000-08       Impact factor: 8.661

5.  Epidemiology of surgically managed pelvic organ prolapse and urinary incontinence.

Authors:  A L Olsen; V J Smith; J O Bergstrom; J C Colling; A L Clark
Journal:  Obstet Gynecol       Date:  1997-04       Impact factor: 7.661

6.  Procedures for urinary incontinence in the United States, 1979-1997.

Authors:  Sarah Hamilton Boyles; Anne M Weber; Leslie Meyn
Journal:  Am J Obstet Gynecol       Date:  2003-07       Impact factor: 8.661

7.  Collagen metabolism and turnover in women with stress urinary incontinence and pelvic prolapse.

Authors:  B H Chen; Y Wen; H Li; M L Polan
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2002

8.  Pelvic organ support in nulliparous pregnant and nonpregnant women: a case control study.

Authors:  Amy L O'Boyle; Patrick J Woodman; John D O'Boyle; Gary D Davis; Steven E Swift
Journal:  Am J Obstet Gynecol       Date:  2002-07       Impact factor: 8.661

9.  Smooth muscle fraction of the round ligament in women with pelvic organ prolapse: a computer-based morphometric analysis.

Authors:  Ozlem Ozdegirmenci; Yildirim Karslioglu; Suat Dede; Sinan Karadeniz; Ali Haberal; Omer Gunhan; Bulent Celasun
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2004-09-08

10.  Estrogen levels and estrogen receptors in patients with stress urinary incontinence and pelvic organ prolapse.

Authors:  J H Lang; L Zhu; Z J Sun; J Chen
Journal:  Int J Gynaecol Obstet       Date:  2003-01       Impact factor: 3.561

View more
  17 in total

1.  TGF-beta 1 is a potential regulator of vaginal tropoelastin production.

Authors:  Peter Takacs; Yanping Zhang; Sujata Yavagal; Keith Candiotti; Nahida Chakhtoura; Carlos A Medina
Journal:  Int Urogynecol J       Date:  2011-11-09       Impact factor: 2.894

2.  HOXA11 promotes fibroblast proliferation and regulates p53 in uterosacral ligaments.

Authors:  Kathleen A Connell; Marsha K Guess; Heidi W Chen; Tara Lynch; Richard Bercik; Hugh S Taylor
Journal:  Reprod Sci       Date:  2009-04-16       Impact factor: 3.060

3.  Implications of the FDA statement on transvaginal placement of mesh: the aftermath.

Authors:  Michelle E Koski; Eric S Rovner
Journal:  Curr Urol Rep       Date:  2014-02       Impact factor: 3.092

Review 4.  Peri-operative physiotherapy to prevent recurrent symptoms and treatment following prolapse surgery: supported by evidence or not?

Authors:  Marielle M E Lakeman; Steven E Schraffordt Koops; Bary C Berghmans; Jan Paul W R Roovers
Journal:  Int Urogynecol J       Date:  2012-11-14       Impact factor: 2.894

5.  Biomechanics of the rat vagina during pregnancy and postpartum: a 3-dimensional ultrasound approach.

Authors:  Andrew Feola; Masayuki Endo; Jan Deprest
Journal:  Int Urogynecol J       Date:  2014-01-23       Impact factor: 2.894

6.  Morbidity and functional mid-term outcomes using Prolift pelvic floor repair systems.

Authors:  Sébastien Kozal; Thomas Ripert; Younes Bayoud; Johan Menard; Ioannis Nicolacopoulos; Laurence Bednarzyck; Frederic Staerman; Stéphane Larré
Journal:  Can Urol Assoc J       Date:  2014-09       Impact factor: 1.862

7.  Characterizing the ex vivo textile and structural properties of synthetic prolapse mesh products.

Authors:  Andrew Feola; William Barone; Pamela Moalli; Steven Abramowitch
Journal:  Int Urogynecol J       Date:  2012-08-11       Impact factor: 2.894

8.  Synthetic graft use in vaginal prolapse surgery: objective and subjective outcomes.

Authors:  Luisa A Wetta; Kimberly A Gerten; Thomas L Wheeler; Robert L Holley; R Edward Varner; Holly E Richter
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-11

9.  HOXA11 is critical for development and maintenance of uterosacral ligaments and deficient in pelvic prolapse.

Authors:  Kathleen A Connell; Marsha K Guess; Heidi Chen; Vaagn Andikyan; Richard Bercik; Hugh S Taylor
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

10.  Diminished vaginal HOXA13 expression in women with pelvic organ prolapse.

Authors:  Kathleen A Connell; Marsha K Guess; Alison Tate; Vaagn Andikyan; Richard Bercik; Hugh S Taylor
Journal:  Menopause       Date:  2009 May-Jun       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.